Rob Henderson, Ph.D.

Dr. Rob Henderson serves as Chief Scientific Officer at Viridian Therapeutics. Rob joined Viridian in 2021 to lead nonclinical science and support the research team. 

Rob joined Viridian from EMD Serono (Merck KGaA) where he was most recently Vice President and Head of Global Program Leadership, as well as the Global Program Lead for the autoimmune program, evobrutinib.  In this role, Rob was responsible for the oversight of the global project teams for the Neurology and Immunology, Fertility, and General Medicine/Endocrine therapeutic areas.  Prior to EMD Serono, he served at Amgen for 11 years where he held various global program manager roles in the Oncology therapeutic area, including the Neupogen/Neulasta franchise and Blincyto teams. Previously, Rob was Director of Product Management for the early-stage oncology programs at Corixa Corporation where he was part of the original research and development group.

Rob started his career in academic research as a cellular immunologist, serving as a Postdoctoral Fellow at the University of Pittsburgh Cancer Institute in the laboratory of Dr. Olivera Finn. Rob holds a Ph.D. in Microbiology and Immunology and a degree in Biology from the University of Virginia.